Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does EMPAGLIFLOZIN Cause Generalised oedema? 16 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 16 reports of Generalised oedema have been filed in association with EMPAGLIFLOZIN (Jardiance). This represents 0.0% of all adverse event reports for EMPAGLIFLOZIN.

16
Reports of Generalised oedema with EMPAGLIFLOZIN
0.0%
of all EMPAGLIFLOZIN reports
13
Deaths
14
Hospitalizations

How Dangerous Is Generalised oedema From EMPAGLIFLOZIN?

Of the 16 reports, 13 (81.3%) resulted in death, 14 (87.5%) required hospitalization, and 1 (6.3%) were considered life-threatening.

Is Generalised oedema Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for EMPAGLIFLOZIN. However, 16 reports have been filed with the FAERS database.

What Other Side Effects Does EMPAGLIFLOZIN Cause?

Diabetic ketoacidosis (3,644) Fungal infection (1,941) Blood glucose increased (1,797) Euglycaemic diabetic ketoacidosis (1,769) Weight decreased (1,661) Urinary tract infection (1,439) Ketoacidosis (1,411) Dizziness (1,372) Nausea (1,333) Vomiting (1,201)

What Other Drugs Cause Generalised oedema?

ADALIMUMAB (357) ETANERCEPT (355) IMATINIB (337) ACETAMINOPHEN (276) RITUXIMAB (261) CYCLOPHOSPHAMIDE (248) ESOMEPRAZOLE (248) ATORVASTATIN (247) PREGABALIN (247) HUMAN IMMUNOGLOBULIN G (228)

Which EMPAGLIFLOZIN Alternatives Have Lower Generalised oedema Risk?

EMPAGLIFLOZIN vs EMPAGLIFLOZIN\LINAGLIPTIN EMPAGLIFLOZIN vs EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN EMPAGLIFLOZIN vs EMPAGLIFLOZIN\METFORMIN EMPAGLIFLOZIN vs EMSAM EMPAGLIFLOZIN vs EMTRICITABINE

Related Pages

EMPAGLIFLOZIN Full Profile All Generalised oedema Reports All Drugs Causing Generalised oedema EMPAGLIFLOZIN Demographics